Retrospective analysis shows improved overall survival and progression-free survival in extensive-stage SCLC, indicating promise for immunotherapy in Indian patients.
Key Points
Atezolizumab combined with etoposide-carboplatin showed median overall survival of 11.0 months in Indian patients.
The study involved 38 patients, predominantly males with extensive-stage small-cell lung cancer and a high smoking history.
High ECOG performance status was associated with inferior survival rates, having a hazard ratio of 2.22.
Immunotherapy combined with standard chemotherapy demonstrated results comparable to international standards for survival outcomes.